Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1.

OBJECTIVE There is little information regarding the pattern of metabolic deterioration before the onset of type 1 diabetes. The goal of this study was to utilize data from the Diabetes Prevention Trial-Type 1 (DPT-1) to obtain a picture of the metabolic progression to type 1 diabetes over a period of approximately 2.5 years before its diagnosis. RESEARCH DESIGN AND METHODS Fifty-four DPT-1 participants (22 in the parenteral trial and 32 in the oral trial) were studied. All had oral glucose tolerance tests (OGTTs) at 6-month intervals from approximately 30 to 6 months before diagnosis. The vast majority also had OGTTs at diagnosis. Changes in OGTT glucose and C-peptide indexes from 30 to 6 months before diagnosis were examined by calculating slopes of the indexes for each individual over that time period. Changes from 6 months before diagnosis to diagnosis were examined by paired comparisons of the OGTT metabolic indexes between the time points. RESULTS Glucose levels increased gradually from 30 to 6 months before diagnosis in both the parenteral and oral groups (P < 0.001 for all indexes). Area under the curve (AUC) C-peptide (P < 0.05) and AUC C-peptide-to-AUC glucose ratio (P < 0.001) values decreased in the oral group; peak C-peptide-to-2-h glucose ratio values decreased in both groups (P < 0.001). In participants who also had OGTTs at diagnosis, AUC C-peptide (parenteral group, P < 0.05) and peak C-peptide (oral group, P < 0.05) values decreased from the last 6 months before diagnosis; stimulated C-peptide-to-glucose ratio values decreased in both groups (P < 0.001). Conversely, fasting C-peptide levels increased in both groups (oral group, P < 0.01). Fasting C-peptide-to-fasting glucose ratio values remained constant throughout the 30-month follow-up. CONCLUSIONS These data indicate that over a period of at least 2 years, glucose tolerance gradually deteriorates as stimulated C-peptide levels slowly decline in a substantial number of individuals who develop type 1 diabetes. However, fasting C-peptide levels are maintained, even at diagnosis.

[1]  C. Valeri,et al.  No evidence for genetically determined alteration in insulin secretion or sensitivity predisposing to type 1 diabetes: a study of identical twins. , 2005, Diabetes care.

[2]  O. Faber,et al.  B-cell function and blood glucose control in insulin dependent diabetics within the first month of insulin treatment , 1977, Diabetologia.

[3]  L. Harrison,et al.  Insulin resistance is a risk factor for progression to Type 1 diabetes , 2004, Diabetologia.

[4]  M. Rewers,et al.  Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. , 2004, Diabetes care.

[5]  J. Ilonen,et al.  Natural history of preclinical IDDM in high risk siblings , 1994, Diabetologia.

[6]  S. Brink,et al.  Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of Type 1 (insulin-dependent) diabetic patients , 1991, Diabetologia.

[7]  Å. Lernmark,et al.  The Fourth International Serum Exchange Workshop to standardize cytoplasmic islet cell antibodies , 1991, Diabetologia.

[8]  K. Alberti,et al.  Impaired glucose tolerance precedes but does not predict insulin-dependent diabetes mellitus: a study of identical twins , 1990, Diabetologia.

[9]  Å. Lernmark,et al.  Islet cell and other organ-specific autoantibodies in all children developing Type 1 (insulin-dependent) diabetes mellitus in Sweden during one year and in matched control children , 1989, Diabetologia.

[10]  G. A. Fleming,et al.  C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. , 2004, Diabetes.

[11]  M. Steffes,et al.  Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. , 2003, Diabetes care.

[12]  Carla J Greenbaum,et al.  Insulin resistance in type 1 diabetes , 2002, Diabetes/metabolism research and reviews.

[13]  C. Greenbaum,et al.  Type I diabetes manifested solely by 2-h oral glucose tolerance test criteria. , 2001, Diabetes.

[14]  P. Bingley,et al.  Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. , 1998, Diabetes.

[15]  M. Knip,et al.  Poor Beta‐cell Function After the Clinical Manifestation of Type 1 Diabetes in Children Initially Positive for Islet Cell Specific Autoantibodies , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[16]  F. Pociot,et al.  Genetic susceptibility markers in Danish patients with type 1 (insulin-dependent) diabetes : evidence for polygenecity in man , 1994 .

[17]  L. Kuller,et al.  Familial and sporadic insulin-dependent diabetes: evidence for heterogeneous etiologies? , 1991, Diabetes research and clinical practice.

[18]  J. Krischer,et al.  A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes. , 1990, The New England journal of medicine.

[19]  A. Ziegler,et al.  Predicting Type I Diabetes , 1990, Diabetes Care.

[20]  E. Bonifacio,et al.  Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes , 1990, The Lancet.

[21]  A. Ziegler,et al.  Life-Table Analysis of Progression to Diabetes of Anti-Insulin Autoantibody-Positive Relatives of Individuals With Type I Diabetes , 1989, Diabetes.

[22]  H. Valkenburg,et al.  TEN-YEAR FOLLOW-UP STUDY OF ISLET-CELL ANTIBODIES AND CHILDHOOD DIABETES MELLITUS , 1989, The Lancet.

[23]  M. Sharf,et al.  Fetal obstructive uropathy [corrected]. , 1988, Lancet.

[24]  H. Chase,et al.  Diagnosis of pre-type I diabetes. , 1987, The Journal of pediatrics.

[25]  G. Eisenbarth,et al.  Competitive Insulin Autoantibody Assay: Prospective Evaluation of Subjects at High Risk for Development of Type I Diabetes Mellitus , 1987, Diabetes.

[26]  E. Gale,et al.  Type I (insulin dependent) diabetes: a disease of slow clinical onset? , 1987, British medical journal.

[27]  S. Yagihashi,et al.  Triad of markers for identifying children at high risk of developing insulin-dependent diabetes mellitus. , 1985, JAMA.

[28]  G. Eisenbarth,et al.  First-degree relatives of patients with type I diabetes mellitus. Islet-cell antibodies and abnormal insulin secretion. , 1985, The New England journal of medicine.

[29]  N. Maclaren,et al.  Ten-Year Prognosis of Impaired Glucose Tolerance in Siblings of Patients with Insulin-dependent Diabetes , 1982, Diabetes.

[30]  J. McNally,et al.  EVIDENCE FOR A LONG PREDIABETIC PERIOD IN TYPE I (INSULIN-DEPENDENT) DIABETES MELLITUS , 1981, The Lancet.

[31]  D. Lezotte,et al.  Islet Cell and Other Organ-specific Antibodies in U.S. Caucasians and Blacks with Insulin-dependent Diabetes Mellitus , 1980, Diabetes.

[32]  D. R. Gamble,et al.  ISLET-CELL ANTIBODIES IN DIABETES MELLITUS , 1976, The Lancet.

[33]  M. Parent,et al.  Letter: Dinitrochlorobenzene sensitisation in congenital syphilis. , 1973, Lancet.